Search Videos by Topic or Participant
Browse by Series:

Iron Chelation Therapy Options for MDS

Panelists: Azra Raza, MD.
Published: Tuesday, Mar 03, 2015
For High-Definition, Click
Iron chelation therapy (ICT) is the primary strategy for reducing iron levels, explains Azra Raza, MD. The two oral ICTs available are deferiprone (Ferriprox) and deferasirox (Exjade). Deferiprone is approved as a second-line treatment for thalassemia and it is not often used in patients with myelodysplastic syndrome (MDS), Raza notes. As a result, deferasirox is generally the preferred therapy for patients with lower-risk MDS.

Deferasirox was the first oral drug approved by the FDA as a treatment for chronic iron overload, in 2005. In MDS, deferasirox is approved for patients with transfusion-dependent, lower-risk disease. In a study that included 341 patients with MDS, deferasirox reduced the median serum ferritin level by 35% in chelation-naïve patients and by 22% in previously chelated patients.

Raza also suggests the use of episodic ICT as another strategy to combat iron overload.
Slider Left
Slider Right
For High-Definition, Click
Iron chelation therapy (ICT) is the primary strategy for reducing iron levels, explains Azra Raza, MD. The two oral ICTs available are deferiprone (Ferriprox) and deferasirox (Exjade). Deferiprone is approved as a second-line treatment for thalassemia and it is not often used in patients with myelodysplastic syndrome (MDS), Raza notes. As a result, deferasirox is generally the preferred therapy for patients with lower-risk MDS.

Deferasirox was the first oral drug approved by the FDA as a treatment for chronic iron overload, in 2005. In MDS, deferasirox is approved for patients with transfusion-dependent, lower-risk disease. In a study that included 341 patients with MDS, deferasirox reduced the median serum ferritin level by 35% in chelation-naïve patients and by 22% in previously chelated patients.

Raza also suggests the use of episodic ICT as another strategy to combat iron overload.
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 2nd Annual European Congress on Hematology™: Focus on Lymphoid MalignanciesDec 30, 20182.0
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Publication Bottom Border
Border Publication
x